Welcome to our dedicated page for Modular Med SEC filings (Ticker: MODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Modular Medical, Inc. (Nasdaq: MODD) files a range of reports and disclosures with the U.S. Securities and Exchange Commission (SEC) that document its activities as a development-stage medical device company focused on insulin delivery technology. This page aggregates those SEC filings and pairs them with AI-powered summaries to help readers understand the key points in each document.
For Modular Medical, current reports on Form 8-K are especially relevant. The company has used 8-K filings to describe material definitive agreements for underwritten public offerings of common stock and accompanying warrants, warrant inducement arrangements, and related gross proceeds. These filings also outline terms such as exercise prices, warrant durations, over-allotment options, and underwriter compensation. Other 8-Ks disclose Nasdaq notices regarding the company’s compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, including the time periods granted to regain compliance.
Registration statements on Form S-3 and other referenced registration statements are important for understanding how Modular Medical registers shares underlying warrants and other securities issued in its financings. Filings also confirm the company’s incorporation in Nevada and its status as a development-stage medical device company, as well as providing context for its capital structure.
On this page, AI-generated overviews highlight the main elements of each filing, such as new financing transactions, warrant terms, listing compliance developments, and references to the company’s insulin delivery technology focus. Users can quickly identify which documents address topics like public offerings, private placements, or Nasdaq communications, while still having access to the full text of the official SEC filings for detailed review.
Modular Medical, Inc. completed a best-efforts public offering of 68,098,000 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants, generating approximately $12 million in gross proceeds before fees and expenses.
The deal included 62,098,000 shares of common stock, 6,000,000 pre-funded warrants, and common warrants to purchase up to 68,098,000 shares, all priced at a combined $0.1762 per share (or pre-funded warrant) and warrant. The common warrants are immediately exercisable at $0.1762 per share and expire five years after issuance, with ownership capped at 4.99% or, at the holder’s election, 9.99% of outstanding common stock after exercise.
Directors and executive officers agreed to 90‑day lock-ups, and the company agreed to limits on variable rate issuances for 45 days after closing. Maxim Group LLC acted as placement agent, receiving a 7% cash fee on gross proceeds plus $100,000 in expense reimbursement.
Modular Medical, Inc. is offering 68,098,000 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 68,098,000 shares, on a best-efforts basis.
The combined public offering price per share with a warrant is $0.1762 (pre-funded package at $0.1752). Net proceeds if fully sold are estimated at approximately
Modular Medical, Inc. is filing an S-1 to offer up to 23,571,007 shares of common stock and accompanying common warrants, plus 47,142,014 shares issuable upon exercise of pre-funded and common warrants, on a best-efforts basis for up to
Modular is a pre-revenue diabetes device company with FDA clearance for its earlier MODD1 pump and a 510(k) filing underway for the Pivot product, which it expects to launch after regulatory clearance. The company discloses substantial doubt about its ability to continue as a going concern, noting cash is not expected to fund operations for the next 30 days without additional capital, and reports an accumulated deficit of
The filing also highlights recent financings, Nasdaq minimum bid-price deficiency with a reverse split already authorized, an increase in authorized common shares to 250,000,000, and heavy reliance on future equity raises and partnerships to fund commercialization and manufacturing of its insulin pumps.
Modular Medical, Inc. entered into a new secured promissory note with its chief executive officer, James E. Besser, creating a $350,000 revolving credit facility. The note carries 12% interest on each draw and matures on March 25, 2026, with all company assets and intellectual property pledged as collateral.
The company has not yet borrowed under this facility. Principal and interest must be repaid by the maturity date or earlier if the company raises more than $2,000,000 in equity financings before maturity. Individual draw requests must be at least $50,000 and cannot exceed the remaining availability under the credit limit.
Modular Medical, Inc. reported higher operating losses for the quarter ended December 31, 2025 as it continues to be a pre-revenue diabetes insulin pump developer. Quarterly research and development expense rose to
For the nine months, the net loss widened to
The company received FDA clearance in September 2024 for its MODD1 insulin pump but plans to commercialize its next‑generation Pivot patch pump instead. A 510(k) submission for Pivot was filed on November 13, 2025, and the company expects potential clearance by March 31, 2026 or shortly thereafter.
To shore up liquidity, Modular Medical raised roughly
Solas Capital Management, LLC and Frederick Tucker Golden report beneficial ownership of 5,326,906 shares of Modular Medical, Inc. common stock, representing about 6.8% of the company’s outstanding common stock.
The position includes 4,424,059 common shares and 902,847 additional shares issuable upon exercise of warrants held by two private funds and another fund they manage. Voting and investment power over all 5,326,906 shares is reported on a shared basis, with no sole voting or dispositive power. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Modular Medical.
Modular Medical, Inc. reported that shareholders approved a charter amendment increasing the company’s authorized common stock from 100,000,000 to 250,000,000 shares. This amendment was filed with the Nevada secretary of state on January 23, 2026, and reflects shareholder approval at the 2026 annual meeting.
At the annual meeting, a quorum representing approximately 69% of the outstanding common shares entitled to vote was present in person, virtually, or by proxy. All nominated directors, including Duane DeSisto, Paul DiPerna, and other candidates listed, were elected to serve until the next annual meeting. The filing also shows that shareholders approved each of the six proposals presented, based on the reported vote totals.
Modular Medical, Inc. is asking shareholders at its January 23, 2026 virtual annual meeting to elect eight directors and approve several key capital and compensation proposals. The board seeks authority to implement, within one year, a reverse stock split of the common stock at a ratio between 1‑for‑5 and 1‑for‑40 without reducing authorized shares, primarily to address Nasdaq’s $1.00 minimum bid-price requirement. A separate proposal would increase authorized common shares from 100,000,000 to 250,000,000, and another would add 3,000,000 shares to the 2017 Equity Incentive Plan. Shareholders will also vote on a non‑binding advisory resolution on executive pay and on ratifying Farber Hass Hurley LLP as auditor for the year ending March 31, 2026. As of the December 24, 2025 record date, 77,676,339 common shares were outstanding.
Modular Medical director Steven Felsher reported buying 60,000 shares of the company’s common stock in an underwritten public offering on
Felsher also acquired warrants to purchase 30,000 shares of common stock at an exercise price of
Modular Medical, Inc. director Philip Sheibley reported buying company securities in an underwritten public offering. On December 11, 2025 he acquired 22,000 shares of common stock, bringing his direct holdings to 97,513 shares. He also acquired warrants with a $0.45 exercise price covering 11,000 shares of common stock, which are immediately exercisable and expire on December 11, 2030, resulting in 11,000 derivative securities held. The filing further notes that on the same date he purchased 60,000 shares of common stock and warrants to buy 30,000 shares at an offering price of $0.77 for each two shares of common stock and one warrant.